Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1998 2
2006 1
2007 1
2008 1
2014 2
2016 4
2017 9
2018 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

19 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD.
Martinez FJ, Rabe KF, Ferguson GT, Fabbri LM, Rennard S, Feldman GJ, Sethi S, Spangenthal S, Gottschlich GM, Rodriguez-Roisin R, Arora S, Siler TM, Siddiqui S, Darken P, Fischer T, Maes A, Golden M, Orevillo C, Reisner C. Martinez FJ, et al. Among authors: orevillo c. Chest. 2017 Feb;151(2):340-357. doi: 10.1016/j.chest.2016.11.028. Epub 2016 Dec 1. Chest. 2017. PMID: 27916620 Free article. Clinical Trial.
24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPD.
Reisner C, Gottschlich G, Fakih F, Koser A, Krainson J, Delacruz L, Arora S, Feldman G, Pudi K, Siddiqui S, Orevillo C, Maes A, St Rose E, Martin U. Reisner C, et al. Among authors: orevillo c. Respir Res. 2017 Aug 18;18(1):157. doi: 10.1186/s12931-017-0636-4. Respir Res. 2017. PMID: 28821260 Free PMC article. Clinical Trial.
A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
Reisner C, Fabbri LM, Kerwin EM, Fogarty C, Spangenthal S, Rabe KF, Ferguson GT, Martinez FJ, Donohue JF, Darken P, St Rose E, Orevillo C, Strom S, Fischer T, Golden M, Dwivedi S. Reisner C, et al. Among authors: orevillo c. Respir Res. 2017 Jan 6;18(1):8. doi: 10.1186/s12931-016-0491-8. Respir Res. 2017. PMID: 28061907 Free PMC article. Clinical Trial.
Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease.
Hanania NA, Tashkin DP, Kerwin EM, Donohue JF, Denenberg M, O'Donnell DE, Quinn D, Siddiqui S, Orevillo C, Maes A, Reisner C. Hanania NA, et al. Among authors: orevillo c. Respir Med. 2017 May;126:105-115. doi: 10.1016/j.rmed.2017.03.015. Epub 2017 Mar 12. Respir Med. 2017. PMID: 28427541 Free article. Clinical Trial.
Erratum to: A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
Reisner C, Fabbri LM, Kerwin EM, Fogarty C, Spangenthal S, Rabe KF, Ferguson GT, Martinez FJ, Donohue JF, Darken P, St Rose E, Orevillo C, Strom S, Fischer T, Golden M, Dwivedi S. Reisner C, et al. Among authors: orevillo c. Respir Res. 2017 Aug 21;18(1):158. doi: 10.1186/s12931-017-0638-2. Respir Res. 2017. PMID: 28826397 Free PMC article. No abstract available.
Corrigendum to "A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD" [Respir. Med. 120 November 2016 16-24].
Tashkin DP, Martinez FJ, Rodriguez-Roisin R, Fogarty C, Gotfried M, Denenberg M, Gottschlich G, Donohue JF, Orevillo C, Darken P, St Rose E, Strom S, Fischer T, Golden M, Reisner C. Tashkin DP, et al. Among authors: orevillo c. Respir Med. 2017 Aug;129:164. doi: 10.1016/j.rmed.2017.06.011. Epub 2017 Jun 30. Respir Med. 2017. PMID: 28732826 Free article. No abstract available.
Erratum: Erratum: Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension™ Delivery Technology Versus Foradil® Aerolizer® in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study.
Sethi S, Fogarty C, Hanania NA, Martinez FJ, Rennard S, Fries M, Orevillo C, Darken P, St Rose E, Strom S, Fischer T, Golden M, Dwivedi S, Reisner C. Sethi S, et al. Among authors: orevillo c. Chronic Obstr Pulm Dis. 2017 Apr 15;4(3):258. doi: 10.15326/jcopdf.4.3.2016.0158. Chronic Obstr Pulm Dis. 2017. PMID: 28853450 Free PMC article.
19 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page